|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Extrahepatic Bile Duct Cancer | |||||
| Gallbladder Cancer | |||||
| Liver Cancer | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Bile Duct Neoplasms | |||||
| Cholangiocarcinoma | |||||
| Gallbladder Neoplasms | |||||
| Liver Neoplasms | |||||
| 3 | More general conditions related to this trial | ||||
| Adenocarcinoma | |||||
| Bile Duct Diseases | |||||
| Biliary Tract Diseases | |||||
| Biliary Tract Neoplasms | |||||
| Carcinoma | |||||
| Digestive System Diseases | |||||
| Digestive System Neoplasms | |||||
| Gallbladder Diseases | |||||
| Liver Diseases | |||||
| Neoplasms | |||||
| Neoplasms by Histologic Type | |||||
| Neoplasms by Site | |||||
| Neoplasms, Glandular and Epithelial | |||||
| 4 | Interventions listed in this trial | ||||
| exatecan mesylate | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| DX 8951 | |||||
| 6 | More general drug interventions related to this trial | ||||
| Antineoplastic Agents | |||||
| Antineoplastic Agents, Phytogenic | |||||
| Enzyme Inhibitors | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Daiichi Sankyo Inc. | |||||